Australia markets closed

Clarus Therapeutics Holdings, Inc. (CRXT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.4300+0.0202 (+4.93%)
At close: 04:00PM EDT
0.4250 -0.00 (-1.16%)
After hours: 07:59PM EDT

Clarus Therapeutics Holdings, Inc.

555 Skokie Boulevard
Suite 340
Northbrook, IL 60062
United States
847 562 4300

Sector(s):Β Healthcare
Industry:Β Drug Manufacturersβ€”General
Full-time employees:Β 16

Key executives

NameTitlePayExercisedYear born
Dr. Robert E. Dudley Ph.D.Founder, Pres, CEO & Director800.67kN/A1955
Mr. Richard Dale PetersonChief Financial Officer583.99kN/A1968
Mr. Frank A. Jaeger M.A., M.B.A.Chief Commercial Officer510.3kN/A1971
Mr. Steve StarkVP of Commercial Analytics & OperationsN/AN/AN/A
Mr. Steven A. Bourne CPAChief Admin. Officer, Sec. & TreasurerN/AN/A1962
Ms. Kara J. StancellVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Rozita PassarellaVP of MarketingN/AN/AN/A
Mr. Mike ClevelandVP of SalesN/AN/AN/A
Dr. Jay Newmark M.B.A., M.D.Chief Medical OfficerN/AN/AN/A
Mr. James HollowaySr. VP of Manufacturing & SupplyN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

Corporate governance

Clarus Therapeutics Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.